In this issue:
ICI-related diarrhoea/colitis in cancer with GI infections
Safety of CAR T-cell therapies
Corticosteroids: impact on CAR T-cell efficacy in large B-cell lymphoma
Microbiome and immunemediated adverse effects in lung cancer
Landscape of ICI therapies for advanced lung cancer
Immune-related adverse events: predictors for ICI efficacy
Pre-existing autoimmune disease and immune-related adverse events
Pembrolizumab for metastatic breast cancer with high mutational burden
Pembrolizumab + ipilimumab after anti-PD-1/L1 failure in melanoma
Ipilimumab ±anti-PD-1 in anti-PD-(L)1-resistant
Please login below to download this issue (PDF)